REGENTIS BIOMATERIALS LTD. (RGNT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RGNT currently has 7.02M outstanding shares. with significant dilution risk as 7.55M authorized shares could dilute existing holders by 107.5%. The company has significantly diluted shareholders by 67.42% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jul 08, 2026 |
F-1 filing: The filing is a registration statement for the resale of up to 3,807,143 ordinary shares by selling shareholders, including shares issuable upon the exercise of pre-funded warrants, ordinary warrants, and placement agent warrants. |
7M | 7.5M |
| May 01, 2026 |
F-1 filing: This is an F-1 filing for an initial offering of Ordinary Shares. |
5.2M | 3.7M |
| Mar 11, 2025 |
F-1 filing: This is an F-1 filing for an initial public offering of Ordinary Shares. The company intends to list its Ordinary Shares on the Nasdaq Capital Market under the symbol 'RGNT'. |
3.9M | 770K |
| Nov 21, 2024 |
RW filing: Regentis Biomaterials Ltd. has requested the withdrawal of its Registration Statement on Form F-1 (File No. 333-268169) because it has elected to abandon the offering described therein. |
N/A | 0 |
| Nov 04, 2022 |
F-1 filing: Regentis Biomaterials Ltd. is offering units, each consisting of one ordinary share and one warrant to purchase one ordinary share, for a total proposed amount of $15,000,000. |
N/A | 0 |